Er mwyn mabwysiadu dull sy’n seiliedig ar dystiolaeth a gwerthusiad trylwyr mae angen i'r diwydiant fferyllol ymgysylltu â AWMSG. Er mwyn gwella'r tebygolrwydd o ganlyniad ffafriol i'r gwerthusiad gan AWMSG fe wnaethom sefydlu Cynllun Mynediad Cleifion Cymru ym mis Ebrill 2012.  Mae hwn yn helpu i sicrhau y gall gostyngiadau cost ar feddyginiaethau newydd gael eu hystyried gan AWMSG yn ystod ei werthusiadau ac mae'n agor ymhellach y cyfle i feddyginiaethau mwy newydd, cost-effeithiol fod ar gael fel mater o drefn yng Nghymru.  Hyd yma, sicrhawyd bod saith o feddyginiaethau newydd ar gael gan ddefnyddio'r cynllun hwn.  Rydym yn edrych ar sut i annog mwy o gwmnïau fferyllol i gymryd rhan a chynnig meddyginiaethau am gost sy'n unol â'u canlyniadau clinigol.
To adopt an evidence-based approach informed by rigorous appraisal requires the pharmaceutical industry to engage with AWMSG. To improve the likelihood of a favourable appraisal outcome by AWMSG we established, in April 2012, a Wales Patient Access Scheme. This helps to ensure cost discounts on new medicines can be considered by AWMSG during its appraisals and further opens up the opportunity for more new, cost-effective medicines to be routinely available in Wales. To date, seven new medicines have been made available using this scheme and we are looking at how to encourage more pharmaceutical companies to participate and offer medicines at a cost in line with their clinical outcomes.